Dr. Tagawa reviewed RLT/TRT in prostate cancer: radium-223 and lutetium show benefit; combos promising, but more data needed on survival and long-term outcomes. The panel discussed RLT in prostate cancer: patient selection, sequencing, and long-term risks (MDS/AML) are key; trials exploring de-escalation and timing strategies.